Peptide Registry

Vials

Capsules

Liquids

a vial of Vesugen 20mg
an info card for VESUGEN

Vesugen

$49.00

  • Contents: Vesugen (Lys-Glu-Asp; KED tripeptide)
  • Form: Lyophilized powder
  • Purity: >99%
Quantity Discount Price
1 - 3 - $49.00
4 - 7 10% $44.10
8 + 18% $40.18
SKU: N/A Category: Brand:

Description

Vesugen is a synthetic tripeptide bioregulator with the sequence Lys-Glu-Asp (KED), developed by Professor Khavinson from vascular tissue extract analysis. It is the vascular endothelium-targeted member of the Khavinson series. KED shares its N-terminal motif with Livagen (KEDA, liver), Prostamax (KEDP, prostate), and implicitly with Thymogen through the lysine-containing family. Thus, Vesugen is the starting point for KED-family structure-activity studies examining how C-terminal variation on the same scaffold affects tissue targeting. It also has one of the better-characterized evidence bases in the specialty research peptide Khavinson catalog.

Chemical Information

  • Chemical Name: Vesugen (Khavinson vascular tissue-derived tripeptide bioregulator)
  • Also Known As: Vesugen peptide complex
  • Compound Class: Short-chain synthetic tripeptide; tissue-specific epigenetic bioregulator (Khavinson series)
  • Sequence: Not established in public literature
  • Molecular Formula: Not established in public literature
  • Molecular Weight: Not established in public literature (consistent with the broader Khavinson class of low molecular weight peptides, <10,000 Da)
  • CAS Number: Not established in public literature

Applications

  • Vascular tissue-specific gene regulation research. Vesugen is modeled on vascular tissue and is proposed to act via direct peptide-DNA interaction within vascular endothelial and smooth muscle cell nuclei, modulating expression of genes involved in vascular tissue regulation — a mechanism shared with other tissue-targeted Khavinson bioregulators such as Cardiogen (cardiomyocytes) and Cartalax (chondrocytes)
  • Comparative cardiovascular bioregulator research. Vesugen and Cardiogen both relate to cardiovascular tissue but target different cell types (vascular versus cardiomyocyte). As a result, researchers often study them together to explore tissue restriction within the cardiovascular research context
  • Cross-tissue bioregulator specificity research. Vesugen shares its intranuclear DNA-interaction mechanism with other short-chain Khavinson peptides. Therefore, it is used alongside tissue-matched and mismatched bioregulators to test whether reported effects are tissue-restricted or tissue-general
  • Note on evidence base: Published data on Vesugen is mostly in Russian-language

Storage and Handling

Store lyophilized powder under refrigeration (2-8C), protected from heat, light, and moisture. As a short-chain peptide, Vesugen is susceptible to proteolytic degradation once reconstituted. Reconstitute immediately before use, keep reconstituted solution refrigerated, and avoid repeated freeze-thaw cycles.

Compliance Notice

Vesugen is for laboratory research use only. They are not for human or veterinary use and carry no therapeutic, diagnostic, or clinical indication. FDA has not evaluated this product. By purchasing this product, the buyer confirms that they will follow appropriate institutional safety procedures and use it exclusively for controlled research.

Frequently Asked Questions

What is Vesugen?

Vesugen (KED) is a synthetic tripeptide bioregulator targeting vascular endothelial cells through direct intranuclear DNA binding. Its documented research targets include endothelin-1 expression normalization, connexin Cx43 gap junction restoration, SIRT1 activation, and endothelial Ki-67 modulation. It is the vascular endothelium representative of the Khavinson bioregulator series and shares its KED sequence core with Livagen (KEDA) and Prostamax (KEDP).

Why is Vesugen useful for KED-family structure-activity studies?

Vesugen (KED), Livagen (KEDA), and Prostamax (KEDP) share the same N-terminal KED tripeptide core but differ in C-terminal identity and tissue target. Vesugen targets the vascular endothelium, Livagen targets the liver and lymphocytes, and Prostamax targets the prostate tissue. This systematic C-terminal variation on a shared scaffold makes the KED family a model system for studying how minimal sequence changes redirect tissue targeting within the Khavinson bioregulator framework — a structure-activity research question that requires all three compounds to be examined comparatively.

How does Vesugen's endothelin-1 research angle differ from other vascular research tools?

Endothelin-1 is a potent vasoconstrictor produced by endothelial cells and elevated in atherosclerotic and inflammatory vascular conditions. Unlike receptor antagonists that block endothelin receptor binding after the protein is expressed, Vesugen normalizes endothelin-1 gene expression at the transcriptional level through intranuclear peptide-DNA interaction. This upstream gene-regulatory approach produces a different experimental research context than receptor-blocking pharmacological tools and is specifically suited to models examining how endothelial gene expression programs change under pathological conditions.

Related products